Primary Site >> Liver Cancer
Gene >> RET
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
Ref: Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. PMID: 11465538 |
Ref: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. PMID: 17178882 |
Ref: Sunitinib induced pyoderma gangrenosum-like ulcerations. PMID: 22027642 Ref: Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma. PMID: 22977516 |
Ref: Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. PMID: 22214462 Ref: Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. PMID: 22836345 |
Ref: Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. PMID: 23700287 Ref: Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method. PMID: 23744782 Ref: Sorafenib and thyroid cancer. PMID: 23818056 Ref: Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis. PMID: 24061866 Ref: Targeted therapies in development for non-small cell lung cancer. PMID: 24574860 |
Ref: Regorafenib. PMID: 24756792 Ref: Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. PMID: 24797128 Ref: Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. PMID: 25197551 |
Ref: Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET. PMID: 25374061 Ref: Lenvatinib: first global approval. PMID: 25795101 Ref: Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. PMID: 25883126 Ref: A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation. PMID: 26237499 Ref: Profile of nintedanib in the treatment of solid tumors: the evidence to date. PMID: 26677336 |
Ref: GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis. PMID: 27167204 |
Ref: Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. PMID: 27704266 Ref: Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma. PMID: 28042325 Ref: Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor. PMID: 28236116 Ref: TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. PMID: 28350084 Ref: RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma. PMID: 28460436 Ref: Cabozantinib in the treatment of hepatocellular carcinoma. PMID: 28703624 Ref: Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. PMID: 29059635 |
Ref: Quantitative (18)F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. PMID: 28918451 Ref: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. PMID: 29433850 Ref: Regorafenib. PMID: 30069758 Ref: Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRalpha, KIT and RET. PMID: 30069768 Ref: Lenvatinib as a therapy for unresectable hepatocellular carcinoma. PMID: 30220234 |